title: Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer.
abstract: Mitochondria are key organelles in mammary cells in responsible for a number of cellular functions including cell survival and energy metabolism. Moreover, mitochondria are one of the major targets under doxorubicin treatment. In this study, low-abundant mitochondrial proteins were enriched for proteomic analysis with the state-of-the-art two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assistant laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) strategy to compare and identify the mitochondrial protein profiling changes in response to the development of doxorubicin resistance in human uterine cancer cells. The mitochondrial proteomic results demonstrate more than fifteen hundred protein features were resolved from the equal amount pooled of three purified mitochondrial proteins and 101 differentially expressed spots were identified. In which, 39 out of these 101 identified proteins belong to mitochondrial proteins. Mitochondrial proteins such as acetyl-CoA acetyltransferase (ACAT1) and malate dehydrogenase (MDH2) have not been reported with the roles on the formation of doxorubicin resistance in our knowledge. Further studies have used RNA interference and cell viability analysis to evidence the essential roles of ACAT1 and MDH2 on their potency in the formation of doxorubicin resistance through increased cell viability and decreased cell apoptosis during doxorubicin treatment. To sum up, our current mitochondrial proteomic approaches allowed us to identify numerous proteins, including ACAT1 and MDH2, involved in various drug-resistance-forming mechanisms. Our results provide potential diagnostic markers and therapeutic candidates for the treatment of doxorubicin-resistant uterine cancer.
authors: Department of Applied Science, National Hsinchu University of Education, Hsinchu, Taiwan.
authors: Yi-Wen
authors: YW
authors: Lo
authors: Szu-Ting
authors: ST
authors: Lin
authors: Shing-Jyh
authors: SJ
authors: Chang
authors: Chia-Hao
authors: CH
authors: Chan
authors: Kevin W
authors: KW
authors: Lyu
authors: Jo-Fan
authors: JF
authors: Chang
authors: Eugenie Wong Soon
authors: EW
authors: May
authors: Dai-Ying
authors: DY
authors: Lin
authors: Hsiu-Chuan
authors: HC
authors: Chou
authors: Hong-Lin
authors: HL
authors: Chan
mesh_terms: D000101:Acetyl-CoA C-Acetyltransferase / Q000235:genetics / Q000378:metabolism*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008291:Malate Dehydrogenase / Q000235:genetics / Q000378:metabolism*; D024101:Mitochondrial Proteins / Q000235:genetics / Q000378:metabolism*; D020543:Proteome / Q000235:genetics / Q000378:metabolism*; D040901:Proteomics / Q000379:methods; D034622:RNA Interference; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014594:Uterine Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; D024101:Mitochondrial Proteins; D020543:Proteome; D004317:Doxorubicin; D008291:Malate Dehydrogenase; C506639:ACAT1 protein, human; D000101:Acetyl-CoA C-Acetyltransferase
keywords: DIGE; doxorubicin; mitochondrial; resistance; uterine cancer
references: Mol Genet Metab. 2006 Apr;87(4):281-3
references: 16622911
references: J Proteomics. 2012 Jun 18;75(11):3158-76
references: 22522123
references: Proc Natl Sci Counc Repub China B. 1994 Apr;18(2):64-70
references: 7915038
references: J Proteomics. 2012 Apr 3;75(7):1991-2014
references: 22270008
references: Curr Drug Metab. 2010 Jan;11(1):115-28
references: 20302569
references: Cancer Chemother Pharmacol. 2006 Dec;58(6):776-84
references: 16532342
references: Funct Integr Genomics. 2011 Jun;11(2):225-39
references: 21246238
references: Gen Physiol Biophys. 2002 Sep;21(3):257-65
references: 12537350
references: Cancer Lett. 2012 Dec 28;325(2):117-24
references: 22750096
references: Cancer Biol Ther. 2007 Aug;6(8):1240-6
references: 17703109
references: Int J Nanomedicine. 2006;1(3):229-39
references: 17717964
references: Cancer Sci. 2003 Jan;94(1):15-21
references: 12708468
references: Anticancer Res. 2006 Sep-Oct;26(5A):3541-6
references: 17094479
references: Mol Cancer Ther. 2008 Mar;7(3):670-8
references: 18347152
references: Biosens Bioelectron. 2013 Sep 15;47:75-9
references: 23562728
references: Curr Biol. 2003 Jan 21;13(2):R71-3
references: 12546810
references: Int J Oncol. 2009 Jun;34(6):1505-11
references: 19424567
references: Cancer Treat Rev. 2008 Aug;34(5):391-406
references: 18358614
references: Chem Cent J. 2009 Sep 09;3:11
references: 19740416
references: Cancer Lett. 2011 Jul 28;306(2):180-9
references: 21470770
references: Hum Pathol. 2009 Dec;40(12):1671-8
references: 19695674
references: Cell Mol Life Sci. 2008 Oct;65(20):3145-67
references: 18581055
references: Biochim Biophys Acta. 2011 Jun;1807(6):735-45
references: 21453675
references: Nat Rev Genet. 2005 May;6(5):389-402
references: 15861210
references: Ryoikibetsu Shokogun Shirizu. 2001;(33):87-8
references: 11462730
references: J Proteomics. 2012 Oct 22;75(18):5822-47
references: 22889595
references: Proteomics. 2005 Jul;5(11):2908-26
references: 15954156
references: Chem Cent J. 2008 Jul 18;2:16
references: 18638390
references: Mol Biosyst. 2011 Jun;7(6):1990-8
references: 21468429
references: Prostate. 2013 Jul;73(10):1028-37
references: 23389923
references: J Proteome Res. 2010 Mar 5;9(3):1302-22
references: 20052998
references: Ryoikibetsu Shokogun Shirizu. 1998;(18 Pt 1):310-3
references: 9590054
references: Oncogene. 2006 Apr 13;25(16):2328-38
references: 16314837
references: Curr Med Chem. 2008;15(26):2648-55
references: 18991627